Erika Adams is the former deputy editor of Eater’s Northeast region, where she covered Boston, Philly, D.C. and New York. Based in Boston, she has spent years covering the local restaurant industry.

Regenerative medicine developer Semma Therapeutics is bringing on Bastiano Sanna, formerly of Novartis’ cell and gene therapy unit and Magenta Therapeutics, to serve as its president and CEO following ...

A startup that wants to change the way we treat type 1 diabetes just raised $114 million. Semma Therapeutics, a company that got its start in 2014, is researching ways to use stem cells that act like ...

Semma Therapeutics, a company developing a cell therapy for Type 1 diabetes, announced today that it has closed a $44 million Series A consisting of equity financing and strategic funding. The Series ...

A Cambridge biotech seeking to develop a treatment for diabetes that would eliminate the need for insulin injections has attracted $114 million in venture capital in a second round of fund-raising.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the appointment of Bastiano ...